Researchers from the renowned Memorial Sloan Kettering Cancer Center in New York have announced a new Phase I study of CAR T-Cell immunotherapy for pleural mesothelioma. They are seeking candidates that meet specific criteria who wish to be included in this important research.
Study Will Assess Safety of Innovative Mesothelioma Treatment
The new mesothelioma study will be led by medical oncologist Roisin E. O’Cearbhaill, M.D. and her co-investigators, medical oncologist Marjorie G. Zauderer, M.D., surgeon David R. Jones, M.D., and interventional pulmonologist Jason Beattie, M.D. It will be a single-arm, open-label test aimed at determining the safety of using genetically engineered autologous T-cells that target mesothelin.
Patients diagnosed with malignant pleural mesothelioma who are accepted into the clinical trial will have some of their T-cells removed and genetically modified so that they recognize mesothelin. They will then be returned to the patients via a catheter that delivers the cells directly into the chest cavity with the hopes that they will find and kill any cancerous cells.
Mesothelioma Patient Eligibility
The study is specifically focused on patients whose mesothelioma has returned despite prior treatment, and it aims at identifying the highest dose of T cells that the patients can tolerate. To be eligible, patients’ mesothelioma must persist despite earlier treatment. They cannot have previously received CAR T cells and must have recovered from any serious adverse effects that they suffered from previous cancer protocols. They must be 18 or older and able to walk and do routine daily activities for over half of their normal waking hours.
Prior to the CAR T cell treatment, patients will receive cyclophosphamide, a chemotherapy drug. Eligible, interested patients can contact get more information by calling 646-608-2091 or emailing cart@mskcc.org.
If you or someone you love has been diagnosed with malignant mesothelioma, participation in a clinical trial can offer great hope. For information about other research, contact the Patient Advocates at Mesothelioma.net at 1-800-692-8608.
